Medications for Osteoporosis

Osteoporosis medications span multiple drug classes, each targeting a different point in the bone remodeling cycle to reduce fracture risk. This page covers the major approved pharmacologic categories, their mechanisms of action, the clinical scenarios that typically prompt their use, and the boundaries that guide prescribing decisions. Understanding these distinctions matters because bone loss is a silent process — the endocrine connection to osteoporosis means that hormonal imbalances frequently drive skeletal fragility before a fracture ever occurs.

Definition and scope

Pharmacologic treatment for osteoporosis encompasses agents formally reviewed and approved by the U.S. Food and Drug Administration (FDA) for reducing fracture risk in adults with established bone loss. The FDA distinguishes between postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis as separate labeled indications — and not every drug holds approval across all three categories.

The clinical threshold for intervention is typically anchored to bone mineral density (BMD) measurement via dual-energy X-ray absorptiometry (DXA), with a T-score of −2.5 or below defining osteoporosis by World Health Organization (WHO) criteria (WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level, 2004). The 10-year fracture probability tool FRAX, maintained by the University of Sheffield, adds fracture probability to BMD data and is referenced in guidelines from the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) to determine when to initiate treatment. A FRAX-estimated 10-year hip fracture probability at or above 3%, or a major osteoporotic fracture probability at or above 20%, supports pharmacologic intervention in U.S. practice (BHOF Clinical Practice Guideline).

For a map of how these treatments fit into the broader endocrinology landscape, the endocrinology authority index provides orientation across all major topic areas.

How it works

Osteoporosis medications fall into two mechanistic categories: antiresorptive agents, which slow osteoclast-driven bone breakdown, and anabolic agents, which stimulate osteoblast-driven bone formation. A third hybrid category — romosozumab — has both effects simultaneously.

Antiresorptive agents

  1. Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) — bind to hydroxyapatite in bone matrix and are internalized by osteoclasts, disrupting the mevalonate pathway and inducing osteoclast apoptosis. Alendronate and risedronate are oral weekly formulations; zoledronic acid is administered as a single annual intravenous infusion.
  2. Denosumab (Prolia) — a RANK ligand (RANKL) inhibitor administered subcutaneously every 6 months. By blocking RANKL, denosumab prevents osteoclast maturation and activation. The FDA label for Prolia was updated in 2022 to include a warning about rebound vertebral fractures upon discontinuation without transition therapy.
  3. Selective estrogen receptor modulators (SERMs) — raloxifene acts as an estrogen agonist in bone tissue, suppressing osteoclast activity, while functioning as an estrogen antagonist in breast tissue.
  4. Hormone therapy — estrogen-based postmenopausal hormone therapy has antiresorptive effects but is not approved as a primary osteoporosis treatment; its fracture data from the Women's Health Initiative (WHI) are used contextually.

Anabolic agents

  1. Teriparatide (Forteo) — a recombinant form of parathyroid hormone (PTH 1-34), administered by daily subcutaneous injection. By providing intermittent PTH exposure rather than continuous elevation, teriparatide shifts the remodeling balance toward formation. Limited to a cumulative lifetime exposure of 2 years per the FDA label, based on osteosarcoma signals in rat studies at supratherapeutic doses.
  2. Abaloparatide (Tymlos) — a PTH-related protein analog (PTHrP 1-34) with the same 2-year lifetime limit and similar daily subcutaneous dosing protocol.

Dual-action agent

Common scenarios

Three clinical situations account for the majority of osteoporosis medication decisions.

Postmenopausal women with T-score ≤ −2.5 or prior fragility fracture. Oral bisphosphonates — alendronate 70 mg weekly or risedronate 35 mg weekly — are typically first-line per BHOF guidance, supported by fracture reduction data across multiple randomized controlled trials. Zoledronic acid 5 mg IV annually serves patients with GI intolerance to oral bisphosphonates or adherence concerns.

Glucocorticoid-induced osteoporosis (GIOP). The American College of Rheumatology (ACR) published updated GIOP guidelines in 2022 (ACR GIOP Guideline 2022) recommending oral bisphosphonates as first-line for medium- to high-risk patients on ≥ 2.5 mg/day prednisone equivalent for ≥ 3 months. The regulatory context for endocrinology shapes how these drugs are reviewed, labeled, and monitored post-approval.

Severe osteoporosis requiring anabolic therapy. Patients with T-score ≤ −3.0 plus multiple prior fractures, or those who have sustained a fracture on antiresorptive therapy, may be candidates for teriparatide, abaloparatide, or romosozumab. Specialist management — often involving endocrinology — is typically required for anabolic agents; see osteoporosis specialist management for referral considerations.

Decision boundaries

Prescribing decisions are constrained by drug-specific contraindications, monitoring requirements, and sequencing rules.

Monitoring after initiation typically includes repeat DXA scanning at 1–2 year intervals, and baseline serum calcium, vitamin D 25-OH, and renal function panels before starting therapy.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)